Dr. Georgie A. Eapen, MD

Dr. Eapen practices at The University of Texas MD Anderson Cancer Center in Houston, Texas, part of The University of Texas System.

Dr. Eapen's NPI, 1467540625, was assigned on October 11, 2006. Dr. Eapen graduated from University of Benin Faculty of Medicine in 1990. Dr. Eapen holds Texas license K6841.

Dr. Eapen's primary practice is The University of Texas MD Anderson Cancer Center, at 1515 Holcombe Blvd, Houston, TX 77030.

Dr. Eapen's primary practice is The University of Texas MD Anderson Cancer Center in Houston, Texas, part of The University of Texas System. The medical group on file is Physicians Referral Service.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Eapen practices. Vendor and product names are available with a free account.

Pulmonary disease is Dr. Eapen's primary specialty in the NPI Registry, under taxonomy code 207RP1001X. Dr. Eapen is board certified in critical care medicine by the American Board of Internal Medicine. Dmand AI has Dr. Eapen's licenses on file in 11 states: Texas, Florida, Georgia, Washington, Alabama, Arizona, Louisiana, Mississippi, Oklahoma, Tennessee and Illinois.

Dmand AI lists asthma, chronic obstructive pulmonary disease (COPD), lung resection, pleural effusion and pneumonia among the conditions Dr. Eapen treats.

CMS data shows 822 Medicare services from Dr. Eapen across 18 procedure codes in 2024, for 356 Medicare patients. Medicare paid $61,283 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 356 Medicare patients who saw Dr. Eapen in 2024. The largest group is 65 to 74, with 191 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 6% are also on Medicaid. Their average risk score is 2.74, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Eapen's median patient age at 70, with 52% women.

In 2024, Dr. Eapen wrote 21 Medicare Part D claims for 13 patients. 62% of them were for generic drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 84 out of 100 for Dr. Eapen for performance year 2024, reported as part of a group. Dr. Eapen accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

Dmand AI links 53 papers to Dr. Eapen, published from 2006 to 2024. 2010 was the busiest year, with 4. The most frequent topics are Lung Neoplasms, Bronchoscopy and Carcinoma, Non-Small-Cell Lung. Dr. Eapen has published most often in J Bronchology Interv Pulmonol. Dr. Eapen's most frequent co-authors are Carlos A. Jimenez, MD, Rodolfo C. Morice, MD and David Edward Ost, MD.

Dmand AI links Dr. Eapen to 1 clinical trial. Conditions studied include Lung Neoplasms and Thoracic Neoplasms.

CMS Open Payments shows 1 general payment to Dr. Eapen from 1 drug or device company in 2017. Food and beverage make up the largest share, 100% of the total. Intuitive Surgical, Inc. paid the most, $29. It also lists 1 research payment totaling $415 in 2016.

Dr. Eapen graduated from University of Benin Faculty of Medicine in 1990.

Dr. Eapen is in network with 8 carriers, including Aetna, Excellus BlueCross BlueShield and United Healthcare. PPO plans come from the most carriers, 6. Check the plan with the practice before a visit.